FDA to Review Potential New Use of XGEVA® (Denosumab) at Oncologic Drugs Advisory Committee Meeting Read more about FDA to Review Potential New Use of XGEVA® (Denosumab) at Oncologic Drugs Advisory Committee Meeting
Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 Read more about Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
Amgen Announces 2012 First Quarter Dividend Read more about Amgen Announces 2012 First Quarter Dividend
Amgen Announces Final Results of Its Tender Offer Read more about Amgen Announces Final Results of Its Tender Offer
Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) Read more about Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
Amgen to Present at the 22nd Annual Oppenheimer Healthcare Conference Read more about Amgen to Present at the 22nd Annual Oppenheimer Healthcare Conference
Amgen Announces Preliminary Results of Its Tender Offer Read more about Amgen Announces Preliminary Results of Its Tender Offer
Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy Read more about Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
The Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate Cancer Read more about The Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate Cancer
